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Mcl1 haploinsufficiency protects mice
from Myc-induced acute myeloid leukemia
Zhifu Xiang,1 Hui Luo,1 Jacqueline E. Payton,2 Jennifer Cain,3 Timothy J. Ley,1
Joseph T. Opferman,4 and Michael H. Tomasson1
1Department of Medicine, Division of Oncology, and 2Department of Pathology and Immunology, Siteman Cancer Center,
Washington University School of Medicine, St. Louis, Missouri, USA. 3OncoMed Pharmaceutical Inc., Redwood City, California, USA.
4Department of Biochemistry, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA.

Antiapoptotic BCL2 family members have been implicated in the pathogenesis of acute myelogenous leukemia
(AML), but the functional significance and relative importance of individual proteins (e.g., BCL2, BCL-XL, and
myeloid cell leukemia 1 [MCL1]) remain poorly understood. Here, we examined the expression of BCL2, BCL-XL,
and MCL1 in primary human hematopoietic subsets and leukemic blasts from AML patients and found that
MCL1 transcripts were consistently expressed at high levels in all samples tested. Consistent with this, Mcl1
protein was also highly expressed in myeloid leukemic blasts in a mouse Myc-induced model of AML. We used
this model to test the hypothesis that Mcl1 facilitates AML development by allowing myeloid progenitor cells
to evade Myc-induced cell death. Indeed, activation of Myc for 7 days in vivo substantially increased myeloid
lineage cell numbers, whereas hematopoietic stem, progenitor, and B-lineage cells were depleted. Furthermore,
Mcl1 haploinsufficiency abrogated AML development. In addition, deletion of a single allele of Mcl1 from fully
transformed AML cells substantially prolonged the survival of transplanted mice. Conversely, the rapid lethality of disease was restored by coexpression of Bcl2 and Myc in Mcl1-haploinsufficient cells. Together, these data
demonstrate a critical and dose-dependent role for Mcl1 in AML pathogenesis in mice and suggest that MCL1
may be a promising therapeutic target in patients with de novo AML.
Introduction
Acute myeloid leukemia (AML) affects 10 in 100,000 individuals in
the United States and is fatal without treatment. Standard chemotherapy consists of a combination of anthracycline and cytarabine
and yields a 5-year survival rate of 20%–30% (1). Despite decades of
clinical research, the treatment for AML has remained essentially
unchanged for 30 years (1). Defects in apoptosis pathways are common and perhaps essential for tumorigenesis and maintenance (2).
Overexpressed antiapoptosis BCL2 family members render tumor
cells more resistant to conventional chemotherapy (3). On the
other hand, all tumor cells retain their normal cell death machinery (4). Thus, therapeutic strategies targeting overexpressed BCL2
or other BCL2 family members are attractive and emerging from a
better understanding of molecular mechanisms underlying apoptosis regulation and of dysregulated pathways for cancer. Indeed,
the identification of antiapoptosis BCL2 family members and
development of BH3 mimetic small-molecular inhibitors has led
to enthusiasm among oncologists (3), but the finding that these
inhibitors may have differential specificity among BCL2 family
members has highlighted the importance of characterizing the
role of individual family members in specific cancer types (5).
The prototypic oncogene Myc encodes a helix-loop-helix leucine
zipper transcription factor with diverse functions, including cell
cycle progression, metabolism, angiogenesis, differentiation, and
apoptosis (6–8). Dysregulated Myc has been found in a large fraction of human cancers, and extensive studies have shed light on the
mechanisms by which Myc overexpression promotes tumorigenesis
(9–12). Retrovirally mediated overexpression of C-Myc (13) or N-Myc
(14) in mouse bone marrow cells rapidly induces an oligoclonal
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AML-like disease characterized by splenomegaly; accumulation of
immature myeloid cells in bone marrow, spleen, thymus, and lymph
nodes; hind limb paralysis; and death within 6 weeks. Myc induces AML in both C57BL/6 and Balb/c strains of mice with similar
latency, and the leukemia is readily transplantable into secondary
recipients (13). Human and mouse Myc genes, and both p62 and
p67 Myc isoforms, all induce AML if expressed at sufficiently high
levels (H. Yung and M.H. Tomasson, unpublished observations).
Expression of Myc via retroviral transduction-transplantation using
Ink4a–/– donor cells, or coexpression of Myc with Bcl2, cooperatively
induces B cell leukemia/lymphoma (13), consistent with the data
generated using B cell–specific transgenic mice (9). However, Ink4a
status and Bcl2 coexpression did not affect AML development in
this model, and, in contrast to lymphomas developing in Myc transgenic mice, we found that AML tumors harbor neither karyotypically detectable chromosomal abnormalities nor mutations in the
Ink4a-p53 tumor suppressor pathway (13). Taken together, these
data suggest that myeloid progenitor cells expressing Myc in bone
marrow transplantation-transduction assays possess an intrinsic
mechanism of resistance to Myc-induced apoptosis.
We sought to evaluate the role of BCL2 family members in the
pathogenesis of AML using a Myc-induced mouse AML model.
We hypothesized that retroviral expression of Myc rapidly induces
myeloid lineage leukemia, at least in part, by cooperating with
intrinsic apoptosis resistance factors of bone marrow progenitor subpopulations. Here, we sought to identify factors required
for AML development by examining human AML samples and
fractionated subpopulations of bone marrow cells from leukemic
mice by Western blot analysis of candidate apoptosis proteins. We
identified several candidate apoptosis gene products that were
differentially expressed between myeloid and lymphoid hematopoietic cells in mice, and focused our validation efforts on the
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Figure 1
MCL1 is the predominant BCL2 family member expressed in primary AML samples. (A) Gene expression profiles were analyzed in 111 de novo
AML samples, and high MCL1 expression was observed in all AML samples. Error bars represent mean ± SD. (B) MCL1, but not BCL2 and
BCL-XL, were highly expressed in all AML subtypes. Expression levels of MCL1, BCL2, and BCL-XL were analyzed in AML samples of different
French, American, and British (FAB) classification subtypes (M0–M7) and in cells from normal donors (sorted CD34+ cells, promyelocytes [Pro],
and PMNs). Each data point represents 1 sample (either patient or sorted normal cells). (C) Elevated MCL1 expression was seen in almost all
AML samples. Western blots of AML cells from newly diagnosed AML patients. Lanes 1–6, AML samples; lane 7, chronic myeloid leukemia
sample; lane 8, K562 cell line; lane 9, normal human bone marrow mononuclear cell control.

BCL2 family member myeloid cell leukemia 1 (Mcl1), based on the
high expression of MCL1 in 100% of human de novo AML samples
examined. We hypothesized that if Mcl1 is critically important for
myeloid leukemogenesis, then decreased Mcl1 gene dosage might
protect mice from Myc-induced AML. Indeed, we found that haploinsufficiency of Mcl1 significantly protected mice from Myc2110
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induced AML, and that Cre-lox–mediated deletion of a single Mcl1
allele prolonged the survival of mice with fully established AML.
The critical sensitivity of the AML disease phenotype to Mcl1 gene
dosage demonstrates that Mcl1 plays a nonredundant role in AML
induction in mice and suggests that MCL1 may play a similar role
in human AML pathogenesis.
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Figure 2
Elevated Mcl1 expression in myeloid leukemia cells from
Myc-induced AML mice. (A) Western blot of protein lysates
prepared from unfractionated bone marrow, spleen (Sp),
and lymph node cells isolated from leukemic mice transplanted with MSCV-Myc (Myc), MSCV-Myc-Ires-Bcl2
(MIB), or vector alone (GFP). (B) Western blot of sorted
Gr-1+ myeloid (G) and B220+ B-lymphoid (B) cells and cells
sorted by GFP expression from MSCV-Myc– or GFP-transplanted mice. Cells were harvested from moribund leukemic mice, typically 4–6 weeks after transplantation, and
from age-matched control mice. Representative blots from
3 independent experiments are shown.

Results
MCL1 expression is consistently high in primary human AML samples.
MCL1 was originally identified as a gene whose expression is
induced during myeloid cell differentiation by the phorbol ester
12-O-tetradecanoylphorbol-13-acetate (TPA), and its antiapoptotic function may play a critical role in the survival of human
leukemia cells (15, 16). We measured transcript levels using
expression profiling from primary bone marrow samples derived
from 111 de novo AML patients; of 174 candidate genes examined, MCL1 transcripts were consistently high in all AML samples
(Figure 1A) and all AML subtypes, whereas BCL2 and BCL-XL
expression levels were relatively low in AML samples (Figure 1B).
In normal human bone marrow cells, MCL1 transcripts increased
with myeloid differentiation and remained high even in mature
polymorphonuclear cells (PMNs); conversely, BCL2 and BCL-XL
transcripts either decreased or remained unchanged with normal
hematopoietic differentiation (Figure 1B). We also examined the
protein levels of MCL1, BCL2, and BCL-XL in bone marrow cells
from the de novo AML patients and found that MCL1 proteins
were expressed at high levels in almost all samples, whereas BCL2
and BCL-XL expression varied (Figure 1C). These data suggest
that MCL1 may play an important and previously unappreciated
role in AML development.
Elevated Mcl1 expression in myeloid leukemia cells from Myc-induced
AML mice. We then sought to test whether Mcl1 expression is
elevated in AML cells in mice from a murine AML model. We
analyzed expression levels of Mcl1 and other BCL2 family members in the Myc-induced AML mouse model (13). In this model,
overexpression of Myc induces an exclusive AML phenotype in
the absence of antiapoptotic mutations, whereas development of
the lymphoid phenotype requires coexpression of Myc with Bcl2.
We hypothesized that myeloid progenitors transformed by Myc
must possess distinct machinery to overcome Myc-induced apoptosis and cause AML phenotype. To test our hypothesis, we used
a transduction-transplantation approach, transplanting unfractionated murine bone marrow cells transduced with murine stem
cell virus (MSCV) carrying Myc (MSCV-Myc) or Myc-Ires-Bcl2 (MSCVMyc-Ires-Bcl2; referred to herein as MIB) into leukemic mice. We
then isolated mononuclear cells from the tissues of these mice and
compared the expression of critical apoptosis proteins with that
The Journal of Clinical Investigation

in control transplanted animals. Bone marrow and spleen cells
from mice with Myc-induced AML (predominantly myeloid blasts;
data not shown) exhibited increased levels of antiapoptotic proteins, especially Mcl1 and Bcl-xL (Figure 2A), but only moderately
increased levels of Mcl1 and Bcl-xL were found in tissues of MIB
mice (mixed myeloid and lymphoid blasts; data not shown). The
lymph nodes from Myc recipients were phenotypically unaffected,
whereas lymph nodes from MIB mice were infiltrated with lymphoid leukemia blasts (B220+CD43+ pre-B cells; data not shown),
and only express modest levels of Mcl1. Furthermore, only the
MIB-expressing mice had substantial levels of Bcl2 expression in
comparison to Myc and vector-only recipients. Proapoptotic BH3only family members PUMA, Bak, and Noxa were elevated in cells
from Myc recipients (Figure 2A). Although Bim expression levels
were elevated in Myc recipients, they were much higher in all tissues from MIB recipients (Figure 2A). These data suggest that the
antiapoptotic proteins Mcl1 and Bcl-xL may be responsible for
evading Myc-induced apoptosis and disease development.
We then used high-throughput flow cytometry to sort myeloid
(Gr-1+) and B lymphoid (B220+) cells from the spleens of Myc,
MIB, and vector-only recipient mice to assess whether the expression of apoptosis-related proteins is lineage specific. Interestingly,
high Mcl1 expression was observed in sorted myeloid cells, but
was relatively low in B-lineage cells (Figure 2B). Bcl-xL was highly
expressed in Myc-transformed — but phenotypically normal —
B cells from Myc mice, but not in immature B leukemic cells from
MIB recipients (Figure 2B). Myeloid leukemic cells also expressed
high levels of proapoptotic proteins Bak, Noxa, and PUMA, but
not Bim (Figure 2B). Together, our results indicate that myeloid
and lymphoid cell populations from normal and leukemic mice
have distinct profiles of pro- and antiapoptotic proteins and that
Mcl1 expression may enable myeloid progenitor cells to evade
Myc-induced apoptosis.
Mcl1 is not a transcriptional target of Myc. Ectopic Myc expression
can prime cells for programmed cell death, in part by downregulating Bcl2 and Bcl-xL (17). We wondered whether Myc activation has the opposite effect on Mcl1 expression. To address this
question, NIH 3T3 cells and Ba/F3 cells were transduced with
an inducible Myc allele, MycER, and Mcl1 expression levels were
analyzed after Myc activation. To confirm activation of Myc, the
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Figure 3
Myc activation does not directly alter Mcl1 expression. (A) Elevated Myc target gene ODC expression upon Myc activation in 3T3 cells.
RT-PCR was performed from RNA collected 0, 2, 4, and 6 hours after 4-OH tamoxifen treatment of MycER-transduced 3T3 cells (lanes 1–4,
respectively) and GFP-transduced cells (0 and 6 hours; lanes 5 and 6, respectively). (B) Mcl1 expression was not changed in transduced
BaF3 cells treated with ethanol (E) or with 4-OH tamoxifen dissolved in ethanol for the indicated times. SV40-transduced mouse embryonic
fibroblasts (MEFs) were used as an Mcl1-positive control. (C) Mcl1 expression was not changed in transduced 3T3 cells treated for 24 hours
with either 4-OH tamoxifen or ethanol. Myc-transduced 3T3 cells were used as a positive control. (D) Elevated Mcl1 expression in bone marrow cells after 7 days of Myc induction along with Gr-1+ cell expansion in bone marrow. Protein lysates were prepared from the mice treated
with DMSO for 7 days (D7) or tamoxifen for 1 or 7days (T1 and T7, respectively). SV40-transduced mouse embryonic fibroblasts and bone
marrow cells of Myc-induced leukemic mice were used as positive controls. Lanes were run on the same gel but were noncontiguous (white
lines). (E) Tamoxifen treatment resulted in relative depletion of B220+ lymphoid cells with concurrent expansion of Gr-1+ myleoid cells in bone
marrow (blue, Gr-1+; red, B220+). FSC, forward scatter; SSC, side scatter. Cells were gated for GFP, and the percentages of Gr-1+ and B220+
events are shown at right. Data are mean ± SD.

expression level of its well-known target gene ornithine decarboxylase (ODC) was used as a readout of Myc activation (18).
ODC transcript levels increased after 2 hours of treatment with
4-OH tamoxifen, confirming Myc activation (Figure 3A). However, Mcl1 expression was analyzed at different time points after
4-OH tamoxifen treatment, and no significant increases in Mcl1
protein levels were observed (Figure 3, B and C).
We also analyzed the Mcl1 expression levels in primary bone marrow cells after Myc induction. There were no changes in Mcl1 protein
levels after 24 hours of in vivo Myc activation (Figure 3D). We found
elevated Mcl1 levels in MycER bone marrow cells after 7 days of
tamoxifen treatment; however, this increase was concomitant with
2112
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expansion of the GFP+GR-1+ cell population (Figure 3E). Together,
these data show that Mcl1 is not a direct transcriptional target of
Myc, but suggest that elevated Mcl1 levels in Myc-induced AML may
be caused by indirect upregulation of Mcl1, or that Myc activation
may provide a selective advantage to Mcl1-expressing cells.
We considered the possibility that one mechanism for high Mcl1
expression in MSCV-Myc mice might be due to selection for cells
with retroviral integration near the Mcl1 locus. Using ligationmediated PCR, we cloned 67 retroviral integration sites from Myc
AML mice (n = 3, 34 clones; Supplemental Table 1), and from control MSCV-GFP–transplanted mice (n = 3, 33 clones; Supplemental
Table 2). We identified a total of 44 unique retroviral integration
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Figure 4
HSC and progenitor populations were not
expanded in Myc-induced leukemic mice.
(A) HSCs (KSL) were decreased, as was
the total progenitor pool (Kit+Sca–Lin–), after
MycER induction for 7 days. CD34+FCγ–
CMPs were comparable between tamoxifen and DMSO treatment groups, a relative
increase of CD34+FCγ+ GMPs was seen in
MycER mice treated with tamoxifen, but
also in control mice, and CD34–FCγ– MEPs
were reduced after Myc induction. Representative flow cytometry plots are shown
from mice transplanted with MSCV-MycER
(n = 3) or MSCV-GFP (n = 3). Numbers
within dot plots represent the percentage of
events within the respective gates. (B) Frequencies of HSCs and progenitors in bone
marrow of MycER mice. Absolute stem and
progenitor cell numbers also decreased
upon Myc induction (not shown). (C) Sorted
KSL cells, a progenitor cell pool (Kit+Sca–
Lin–), and lineage-committed cells (Kit+Lin+)
were transduced with Myc or GFP vector
alone and plated in methylcellulose media
in the absence or presence of cytokines.
Myc induction increased cytokine-dependent progenitor colonies that failed to
self renew. Myc also induced replatable
cytokine-independent colony formation,
and, surprisingly, Kit+Lin+ cell–derived colonies increased dramatically after third plating. Vector-transduced cells gave rise only
to rare, non–self-renewing colonies (not
shown). Kit–Lin+ cells were sorted but were
substantially dead (Trypan blue–positive)
after a single day and were not plated. Data
in B and C are mean ± SD.

sites, none of which were close to the Mcl1 locus. Notably, 86% (38
of 44) of the integration sites were nonrecurring. A single site of
integration (Prkcbp1 locus) was responsible for 71% (21 of 29) of
the recurrent clones and was found in both MSCV-Myc (10 clones)
and MSCV-GFP (11 clones) mice. These data are consistent with
earlier Southern blot integration analysis (13) and support our
model that the development of AML in the MSCV-Myc model is
independent of retroviral integration site.
HSC and early progenitor cell populations are not expanded in Mycinduced AML. In WT mice, Mcl1 is highly expressed in HSCs, and
its expression level decreases in further differentiated progenitor
cells: common myeloid progenitors (CMPs), common lymphoid
progenitors (CLPs), megakaryocyte erythroid progenitors (MEPs),
and granulocyte monocyte progenitors (GMPs) (19). One explanation for the elevated Mcl1 levels in Myc AML cells may be the
relative increase of HSC and myeloid progenitor populations in
Myc-induced AML. To monitor HSCs and progenitor cells in vivo,
we retrovirally expressed inducible MycER into the bone marrow
of WT mice using a bone marrow transplant assay (absent antiapoptotic mutations) and monitored the effects of Myc induction
on myeloid lineages by flow cytometry. At 3 weeks after bone marThe Journal of Clinical Investigation

row transplant, robust donor engraftment was confirmed by flow
cytometry (40%–60% GFP+ peripheral mononuclear cells; data not
shown). Recipient mice were then treated with tamoxifen or the
carrier DMSO daily for 7 days to induce Myc expression, and bone
marrow mononuclear cells were harvested for analysis. Forward versus side scatter profile of bone marrow with back gating to indicate
cell lineages confirmed the expansion of myeloid cells in contrast to
reduction of the B cell population (Figure 3E). Bone marrow stem
and progenitor cell populations were then analyzed by flow cytometry. Myc induction did not significantly increase the relative or
absolute numbers of Kit+Sca+Lin– (KSL) or immunophenotypically
defined myeloid progenitor cells (e.g., CMPs, GMPs, and MEPs; Figure 4, A and B). There was a modest apparent increase in the relative
abundance of GMPs (CD34+FCγ+) upon Myc induction, but this
effect was nonspecific, as it was observed in MSCV-GFP control mice
treated with tamoxifen as well (Figure 4A). Thus, Myc induction
did not significantly increase HSC and myeloid progenitor pools
in vivo, and Mcl1 elevation was not caused by increased HSCs and
myeloid progenitors after Myc activation.
Myc confers self-renewal ability to committed myeloid progenitor cells.
As Myc induction did not increase the percentage and absolute
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Figure 5
Mcl1 haploinsufficiency protects mice from Myc-induced AML. (A)
Kaplan-Meier survival analyses of mice transplanted with Myc or MIB.
Congenic Mcl1fl/WT or Mcl1fl/null mice were used as bone marrow donors
as indicated. Note the differences in time scale between the graphs.
(B) Mcl1fl/null cells failed to support transformation by Myc. GFP+ cells
in Mcl1fl/WT versus Mcl1fl/null recipients were determined by FACS
before transplantation in bone marrow, at 3 weeks after transplantation in peripheral blood (PB), and at 6 weeks after transplantation in
bone marrow. FCS, forward scatter. Numbers denote the percentage
of events falling within the respective gate. Data are mean ± SD. (C)
Mx1-Cre–mediated deletion of 1 Mcl1 allele from established AML
cells significantly prolonged the survival of secondary recipients. Leukemia cells from primary recipients of Mx1-CreMcl1fl/WT bone marrow
transduced with Myc or MIB were transplanted into secondary recipients treated with pIpC or PBS. (D) PCR amplification of the 390-bp
Mcl1fl and 340-bp Mcl1WT alleles from transplanted mice. Lane 1, Myc
Mcl1fl/WT primary transplant; lane 2, MIB Mcl1fl/WT primary transplant;
lane 3, Myc Mcl1fl/WT secondary transplant after pIpC treatment; lane 4,
MIB Mcl1fl/WT secondary transplant after pIpC treatment; lane 5, MIB
Mcl1fl/WT secondary transplant after pIpC treatment (spleen cells); lane 6,
B6 129 Mcl1fl/WT pIpC-treated spleen cells; lane 7, B6 129 Mcl1fl/WT
untreated control; lane 8, C57B6 WT control.

number of early hematopoietic cells (Figure 4A), we assessed its
effect on self renewal using methylcellulose serial replating assays.
Normal KSL cells, early progenitors (Kit+Sca–Lin–), and lineagecommitted cells (Kit+Lin+) isolated from WT mice were transduced
with Myc or vector alone and then plated in methylcellulose either
with or without cytokines. GFP-transduced KSL, early progenitor,
and lineage-committed cells failed to form colonies after second
plating in methylcellulose culture in the presence or absence of
cytokines (Figure 4C and data not shown). In the presence of
cytokines, Myc expression dramatically increased the number of
initial colonies in KSL, early progenitors, and lineage-committed
cells and conferred the ability to form colonies after multiple serial
platings (Figure 4C). Notably, Myc expression conferred cytokineindependent colony formation activity to stem/progenitor cells
and even to committed myeloid cells. These colonies could be
serially replated in cytokine-free methylcellulose medium up to 5
times (Figure 4C and data not shown), which suggests that Myc is
capable of conferring self-renewal activity to myeloid progenitor
cells, including lineage-committed cells.
Mcl1 haploinsufficiency abrogates Myc-induced AML in mice. To
genetically test whether elevated Mcl1 expression is required for
Myc-induced AML development, we expressed Myc into bone marrow cells derived from Mcl1 gene–targeted normal mice and monitored disease development. As anticipated, Myc induced rapid
fatal AML (mean survival, 56 ± 5 days) in Mcl1 WT (Mcl1fl/WT)
mice (which were phenotypically identical to the phenotype previous reported; ref. 13) that was characterized by leukocytosis,
splenomegaly, and hind limb paralysis with 100% penetrance
2114
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(Figure 5A). However, Myc failed to cause disease in Mcl1-haploinsufficient (Mcl1fl/null) recipients (Figure 5A). We monitored the
transduced (GFP+) cells in peripheral blood and bone marrow at
3 and 6 weeks after transplantation, respectively. In Mcl1fl/null
recipients, GFP+ cells were only 3.9% ± 1.3% in peripheral blood
(versus 64% ± 2.1% in Mcl1fl/WT recipients) and less than 3% in bone
marrow (versus greater than 90% in Mcl1fl/WT recipients; Figure
5B). As reported previously (19), complete loss of Mcl1 expression
(i.e., Mcl1null/null) caused significant loss of early hematopoietic
progenitor populations, including HSC and bone marrow ablation, whereas Mcl1fl/null mice had relatively normal hematopoiesis
and HSC/progenitor populations. To control for the possibility
of a previously unrecognized bone marrow phenotype in Mcl1fl/null
mice, we repeated our bone marrow transduction-transplantation
experiments coexpressing Bcl2 with Myc (i.e., MIB to Mcl1fl/WT and
MIB to Mcl1fl/null), and all recipients developed leukemia with rapid
disease latency (Figure 5A and data not shown).
To further elucidate the role of Mcl1 in Myc-induced leukemia, we
measured the effect of deleting 1 copy of Mcl1 in fully transformed
leukemia cells. We harvested leukemia cells from moribund Mx1Cre–expressing Mcl1fl/WT mice transduced by Myc alone or MIB and
injected them into secondary recipients treated with polyinosinicpolycytidylic acid (pIpC) to mediate Cre deletion or with control
PBS. Deletion of a single Mcl1 allele from Myc-induced Mcl1fl/WT
leukemia cells significantly prolonged the survival in secondary
recipient mice treated with pIpC compared with that in the PBStreated mice (n = 5, P = 0.0026; Figure 5C). In contrast, deletion of
1 copy of Mcl1 from MIB-induced Mcl1fl/WT leukemia cells had no
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Figure 6
Pharmacologic suppression of Mcl1 expression
inhibits growth of murine and human AML cells. (A)
Western blot of Mcl1 protein levels in lysates prepared from MSCV-Myc AML cells treated in liquid
culture for the indicated times with flavopiridol. NT,
nontreated cells at 6 hours. Mouse embryonic fibroblasts were used as protein control. Ratio of Mcl1
to actin protein levels, quantified by densitometry,
are shown below. (B) Dose-dependent flavopiridol
suppression of MSCV-Myc cytokine-independent
methylcellulose colony growth. At flavopiridol doses
less than 1 μM, growth of normal cytokine-dependent bone marrow progenitors was not affected
(not shown). (C) Survival of mice secondarily transplanted with MSCV-Myc AML cells was significantly
prolonged by flavopiridol treatment. (D) MTT assay
measurement of primary human AML cell growth in
the presence of flavopiridol. Results from 4 separate
patient samples, plated in triplicate, are shown. Data
in B and D are mean ± SD.

effect on the survival of the secondary recipients treated with pIpC
compared with PBS-treated mice (n = 5, P = 0.33; Figure 5C). To
determine the mechanism by which Myc-induced leukemia progressed in Mcl1fl/WT mice, we examined the success of recombination in leukemic mice. Leukemic cells from Myc mice revealed an
unrecombined Mcl1fl allele, whereas MIB cells demonstrated complete excision (Figure 5D). These data suggest that Myc-induced
leukemic cells in pIpC-treated secondary mice were selected from
a small population of cells harboring unrecombined WT Mcl1.
These results demonstrate that the antiapoptotic function of Mcl1
plays a crucial role in Myc-induced leukemia development and
maintenance in mice.
Finally, we sought to assess the potential of MCL1 as a target
for drug therapy in AML patients. Flavopiridol, a semisynthetic
flavonoid, is a protein kinase inhibitor that effectively reduces
Mcl1 transcription in a variety of cell contexts (20). We found that
flavopiridol rapidly and significantly decreased Mcl1 protein levels
in bone marrow AML cells from leukemic MSCV-Myc mice (Figure
6A) and suppressed the growth of MSCV-Myc cells ex vivo (Figure
6B). Flavopiridol also significantly prolonged the survival of mice
secondarily transplanted with MSCV-Myc AML cells (Figure 6C).
Drug treatment also suppressed the growth of cultured primary
human AML cells ex vivo in a dose-dependent manner (Figure 6D).
These data provide support for the development of MCL1-targeted
therapies in patients with AML.
Discussion
MCL1 is implicated in the pathogenesis of B cell malignancies,
including B cell lymphoma (21, 22), multiple myeloma (23),
and chronic lymphocytic leukemia (24), but the role of MCL1 in
myeloid malignancy remains poorly defined. MCL1 is a unique
BCL2 family member, characterized by rapid induction and degradation in response to extracellular stimuli that encompass a
large range of growth factors, cytokines, and inducers of apoptosis (15). MCL1 expression is carefully regulated by RNA transcription, posttranscriptional splicing, posttranslational cleavage, and
phosphorylation (25). Kaufmann et al. found that MCL1 protein
The Journal of Clinical Investigation

levels are heterogeneous in AML patient cells, but that the levels of
MCL1 protein expression increase in samples at the time of disease
relapse after chemotherapy (26). Any antiapoptotic BCL2 family member can cooperate with Myc in leukemogenesis (27), but
to our knowledge, the specific functional significance of MCL1
expression in AML has not been demonstrated previously.
We found high-level MCL1 transcript expression in 111 of 111
untreated de novo AML patient bone marrow samples, including all AML subtypes, and observed abundant MCL1 protein
expression in 6 of 7 AML patient samples examined (Figure 1).
The antiapoptotic family members BCL2 and BCL-XL were also
expressed in patient AML samples, albeit less consistently. Expression of BCL2 has been associated with poor prognosis in AML
(3). The BCL2 family members are likely to be functionally redundant in cancer (27). Our data suggest that upregulation of MCL1
is an early event in AML pathogenesis, and BCL2 and BCL-XL
upregulation may occur later during the process of clonal evolution. Our gene profiling data suggested that MCL1 might play an
important role in AML pathogenesis, and we next evaluated the
role of Mcl1 in a murine model of AML.
We examined the expression of apoptosis-regulating proteins
and identified a unique antiapoptotic profile in leukemic blast
cells isolated from moribund AML mice (Figure 2A). Among the
differences observed, Mcl1 protein was uniformly expressed at
higher levels in AML cells than in normal or lymphoid leukemia
cell populations (Figure 2B). We focused on the role of Mcl1 in our
murine model because of the high MCL1 transcript expression levels observed in human AML cells (Figure 1). Recent work has suggested that in a subset of AML patients, activating mutations in
the FLT3 receptor tyrosine kinase may induce high MCL1 expression (28, 29). What mechanisms explain the high-level Mcl1 protein expression in Myc-induced AML cells? We favor the hypothesis
that Myc overexpression upregulates Mcl1 expression in myeloid
progenitor cells indirectly. Myc induction directly suppresses the
expression of Bcl2 and Bcl-xL antiapoptosis family members in
both primary myeloid and lymphoid cells (30, 31). We found that
activation of Myc in different cell types did not markedly increase
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Mcl1 transcript or protein levels at early time points (Figure 3, B
and C), which demonstrated that Mcl1 is not a direct transcriptional target of Myc. Instead, we consistently observed increased
Mcl1 expression only after prolonged expression of Myc (Figure
3D), indicative of an indirect mechanism of Mcl1 induction.
The composition of the bone marrow was dramatically altered
by Myc induction (Figure 3E). We found significant differences in
the way myeloid and lymphoid bone marrow lineages respond to
Myc activation, which may explain why high-level Myc expression
induces exclusively myeloid-lineage leukemia in this AML model
(13). After 7 days of Myc induction, absolute numbers of B-lineage
cells declined, whereas the absolute number of myeloid lineage
cells rose substantially (Figure 3E). Murphy et al. recently found
that lower dosages of Myc can promote cell growth without inducing apoptosis (32), but MSCV-Myc–reconstituted mice expressed
Myc at higher levels in myeloid leukemia cells relative to other cell
types (e.g., B lymphoid cells), which suggests that the rapid induction of AML by retroviral expression of Myc proteins is unlikely to
be explained by subthreshold Myc protein levels.
To determine whether Myc expression was selecting for a
Mcl1-expressing bone marrow population, we next examined
the effects of Myc induction on HSC and progenitor cell populations (Figure 4). HSCs expressed Mcl1 at higher levels compared
with defined myeloid progenitor cell populations (e.g., CMPs
and GMPs; ref. 19), and we thought that Myc induction might
expand the HSC population. Instead, Myc induction caused HSC
and progenitor cell populations to decline (Figure 4, A and B).
The shift we observed, from HSCs and progenitor cells to more
mature (i.e., Lin+) cells, was consistent with the role of Myc as
a promoter of cell differentiation (33), but failed to explain the
development of leukemia in this model. In a parallel experiment,
we transduced purified HSC and progenitor cell populations
with Myc and assayed transformation by methylcellulose colony
assays. Remarkably, Myc conferred self-renewal activity to more
mature lineage-committed progenitor cells (Figure 4C). Leukemia-associated oncogenes have the ability to transform progenitor cells (34). Taken together, these data suggest that high Mcl1
expression in more mature committed myeloid progenitor cells
cooperates with oncogene expression to induce AML.
Using Mcl1 gene-targeted mice as donors for bone marrow
transduction-transplantation experiments, we demonstrated
that haploinsufficiency of Mcl1 was sufficient to significantly
protect mice from the development of Myc-induced AML. Mcl1
heterozygous bone marrow cells transduced with Myc failed to
maintain high Myc expression levels, and mice transplanted with
Mcl1fl/null cells were extremely resistant to AML development (Figure 4). In a second set of experiments, AML was generated using
Mcl1fl/WT donor cells, and leukemic bone marrow from these moribund mice was transplanted into secondary recipients treated with
pIpC. The excision of a single Mcl1 allele from MSCV-Myc AML
cells significantly prolonged the survival of secondary recipient
mice. Coexpression of Bcl2 restored the ability of Myc to induce
fatal leukemias in Mcl1fl/null cells, which demonstrated that Mcl1
loss did not otherwise affect the target cells of leukemic transformation. Although the bulk of our data point to absolute dependence on Mcl1 for protection from oncogene-induced apoptosis,
this remains to be formally proven, particularly with regard to primary human AML cells.
Our finding that AML development and maintenance were
significantly dependent on Mcl1 gene dosage has important
2116
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clinical implications. Mcl1 is required for normal bone marrow
hematopoiesis, and conditional, complete knockout of Mcl1 causes
hematopoietic failure in mice (19). No phenotype has previously
been reported in Mcl1 heterozygous mice (19), but we found here
that in the setting of Myc-induced AML, the survival of mice was
significantly prolonged by reducing Mcl1 dose by 50%. Complete
inhibition of Mcl1 would likely have profound effects on normal
hematopoiesis, and our data suggest that a therapeutic window
exists in which partial reduction of Mcl1 dosage may inhibit leukemogenesis without affecting normal hematopoiesis.
These data support the development of novel MCL1-targeted
agents for AML patients. The MSCV-Myc murine AML model
may be useful for characterizing candidate pharmaceutical compounds for Mcl1 activity. Small-molecule inhibitors targeting
the BH3-binding groove of prosurvival BCL2 family members
(i.e., BH3 mimetics) are currently in clinical development (5, 35).
Preclinical studies have suggested that BH3 mimetics may have
activity in AML and that responses to these compounds may
depend on the expression patterns of individual BCL2 family
members (36). Additional studies are required to identify AML
patient subsets in which specific BCL2 family members are relevant, and may require the development of methods to quantify
expression of different BCL2 family members at the protein level
in patient samples. Moreover, small-molecule inhibitors may
have activity in AML by targeting MCL1 expression indirectly.
For example, inhibiting the PI3K/AKT signal transduction
pathway using the mammalian target of rapamycin (mTOR)
inhibitor rapamycin represses Mcl1 transcription (37), and flavopiridol, an inhibitor of cyclin-dependent kinases (CDKs; ref.
38), rapidly downregulates Mcl1 levels (20, 39). We found that
flavopiridol modestly suppressed the growth of unscreened
primary human AML cells (Figure 6D). The response of human
AML cells to any treatment is susceptible to individual patient
genetics, and future work will allow us to identify patients that
will benefit specifically from Mcl1-targeted drugs.
Methods
Plasmid DNA constructs and retrovirus production. Retroviral constructs MSCVMyc-Ires-GFP and MIB (i.e., MSCV-Myc plus Bcl2) have been described previously (13). MycER was provided by G. Evan (UCSF, San Francisco, California,
USA) and was subcloned into MSCV-IRES-GFP retroviral vector backbone.
Replication-incompetent retroviral supernatant was made according to
the calcium coprecipitation protocol as described previously (13). Retroviral titers of MSCV-Myc and MSCV-MycER was determined by flow cytometry analysis of the GFP+ cells in retrovirally transfected 3T3 cells, and
MIB viral titer was determined by measuring the copy number of proviral
Psi-sequence in transfected cells by real-time PCR.
Bone marrow transduction and transplantation. Bone marrow cell harvesting, transduction, and transplantation were carried out according to
the method previously reported (13). BALB/c and C57BL/6 donor mice
(6–7 weeks old) were obtained from Jackson Laboratories. Mcl1 conditional knockout mice (Mx-1CreMcl1fl/WT and Mx1-CreMcl1fl/null; referred to
herein as Mcl1fl/WT and Mcl1fl/null, respectively) were provided by J. Opferman
(St. Jude Children’s Research Hospital, Memphis, Tennessee, USA). Mononuclear bone marrow cells were spinfected twice, on days –1 and 0 (13).
Bone marrow cells (1 × 106) were injected i.v. into lethally irradiated syngeneic BALB/c (800 cGy), C57BL/6, or C57BL/6 129 (1,200 cGy) mice. Secondary transplants were performed by injecting i.v. 5 × 105 unsorted mononuclear spleen cells isolated from moribund primary transplant recipients
into secondary syngeneic recipient mice treated with 500 cGy gamma
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irradiation. To induce recombinase activity in the secondary recipients of
Mcl1fl/WT Myc leukemia cells, 400 μg pIpC (Sigma-Aldrich) was injected i.p.
into each recipient mouse daily for 3 days before irradiation.
Induction of Myc in vivo. Unfractionated murine bone marrow cells were
transduced with MSCV-MycER retrovirus and subsequently transplanted
into syngeneic recipient mice. Engraftment was documented at 3 weeks
after transplant using flow cytometry detection for robust GFP expression
in peripheral blood cells. Mice were then treated once daily with tamoxifen (0.5 mg/mouse) for 7 days by i.p. injection. In vitro induction of Myc
was performed by applying 4-OH tamoxifen to culture medium to a final
concentration of 250 nM.
Mouse analysis. Recipient mouse monitor, tissue, and mononuclear cell
preparation and staining were carried out as described as previously (13).
Kaplan-Meier and significance analyses were performed using Statview
software (SAS Institute). Fluorescence-conjugated antibodies were used to
recognize lineage markers of Gr-1, Mac-1, B220, IgM, CD4, and CD8 (BD
Biosciences — Pharmingen).
For analysis of progenitor populations, the unfractionated bone marrow
cells were stained as described previously (40). Briefly, PerCP-Cy5.5–conjugated CD3e (clone 145-2C11), CD4 (clone RM4-5), CD8a (clone 53-6.7),
CD19 (clone 1D3), CD45R (clone RA3-6B2), TER119 (clone TER-119),
CD127 (clone SB/199), and GR1 (clone RB6-8C5) were used for lineage
markers (BD Biosciences — Pharmingen). Cells were also stained using biotin-conjugated CD34 (clone RAM34), PE-conjugated streptavidin, allophycocyanin-conjugated Sca-1 (clone D7), PE-Cy7–conjugated CD16/32 (clone
93), and allophycocyanin–Alexa Fluor 750–conjugated CD117 (clone 2B8)
antibodies obtained from eBiosciences. Data was collected from 5 × 106
cells using a MoFlo flow cytometer (Dako) and was analyzed using FloJo
software (Tree Star). Studies in animals were approved by the Washington
University Animal Study Committee (St. Louis, Missouri, USA).
Methylcellulose colony assays. Whole bone marrow cells from 6- to 8-weekold C57BL/6 mice (Taconic Farms) were prepared and transduced as
described above. HSCs and progenitor cells were sorted from whole bone
marrow cells, stained as described above, and subsequently plated into
12-well cell culture plates (approximately 1–63 × 104 cells/well) and transduced with retroviral supernatants by incubation for 12 hours at 32°C in
transplant media as described above. Cells were then transduced again by
centrifugation at 900 g for 90 minutes in the presence of 5 μg/ml polybrene
(American Bioanalytical) and allowed to recover at 37°C for 3 hours.
The colony formation assay was carried out using 12-well untreated
cell culture plates and either cytokine-containing (SCF, IL-3, IL-6, or
EPO) methylcellulose medium MethoCult M3434 (StemCell Technology) or cytokine-free medium MethoCult M3234 (StemCell Technology).
For unfractionated bone marrow cells, 4 × 104 cells/well for MethoCult
M3434 and 4 × 105 cells/well for MethoCult M3234 were plated in triplicate. For sorted hematopoietic cells, cells were washed twice with PBS
and plated into MethoCult M3434 (400 KSL, 800 Kit+Sca–Lin–, and 2 × 104
Kit+Lin+ per well) or MethoCult M3234 (4,000 KSL, 8,000 Kit+Sca–Lin–, and
2 × 105 Kit+Lin+ per well). Colonies containing at least 30 cells were counted 9 days after plating. The GFP+ colony was counted under fluorescent
reverse microscope. For serial replating analysis, pooled colonies were
washed 3 times with PBS and replated into same methylcellulose medium
(MethoCult M3434, 4 × 104 cells/well; MethoCult M3234, 4 × 105 cells/
well) in triplicate. Colonies were counted 9 days after replating.
Flavopiridol treatment. Flavopiridol (Sigma-Aldrich) was prepared in
water, and the flavopiridol concentrations were determined by serial
dilution. The final concentrations of 0, 0.01, 0.1, and 1 μM were used for
liquid cultures of Myc mouse AML cells and primary human AML cells
and for colony formation culture of Myc AML cells. MTT assay used to
evaluate the effect of flavopiridol on human AML cells has been described
The Journal of Clinical Investigation

preciously (41). The primary human AML cells used in this assay were
provided by T. Fehniger (Washington University School of Medicine, St.
Louis, Missouri, USA). Flavopiridol was diluted with PBS and injected i.p.
into Myc secondary recipient mice.
Western blot analysis. Protein lysate preparation and Western blots were
performed following standard protocols as described previously (13). Antibodies used to stain the membrane were as follows: Myc (catalog no. sc788), Mcl1 (catalog no. sc-819), Bcl2 (catalog no. sc-7382), Noxa (catalog
no. sc-22764), and PUMA (catalog no. sc-20534) from Santa Cruz Biotechnology Inc.; Bcl-xL (catalog no. 610211) from BD Biosciences — Pharmingen; XIAP (catalog no. 2042) from Cell Signaling Technology; Bim (catalog
no. 202000) from Calbiochem; and Bak (catalog no. 06-536) from Upstate.
To assess protein loading, blots were stripped and reprobed with anti–
β-actin antibody (Sigma-Aldrich).
Expression profiling and data analysis. AML patient samples were
obtained from patients with de novo AML, following informed consent,
as described previously (42). Human subject research was approved by
the Washington University Human Research Project Office (HRPO) and
the Siteman Cancer Center Protocol Monitoring and Review Committee (PRMC). Bone marrow RNA samples were generated from 111 AML
patients that fulfilled criteria including age greater than 18 years, at least
30% bone marrow involvement by leukemia, at least 2 cytogenetic abnormalities, and no previous therapy.
Bone marrow aspirates were obtained from consented de novo AML
patients, and RNA was prepared from unfractionated snap-frozen
cell pellets. Total cellular RNA was purified using TRI zol reagent
(Invitrogen), quantified using UV spectrometry (Nanodrop Technologies), and qualitatively assessed using a RNA NanoChip assay with BioAnalyzer 2100 (Agilent Technologies). Samples were labeled and hybridized to Affymetrix Human Genome U133 Plus 2.0 Arrays (Affymetrix)
using standard protocols in the Siteman Cancer Center Multiplexed
Gene Analysis Core Facility. The experiments were performed in triplicate. To perform interarray comparisons, the raw scan data from each
array were scaled to a target intensity of 1,500 using statistical algorithm MAS 5 in Affymetrix GCOS version 1.2 software. Scaled data for
each array were merged with updated gene annotation data for the array.
Data visualization and further analysis were performed with functional
genome in the Decision Site (Spotfire).
According to the most updated annotations available from EntrezGene,
UniGene, and Gene Ontology databases and manual curation, we identified 174 apoptosis- and AML-related probe sets on the U133 Plus 2.0 array.
Average signal intensity of these probe sets was calculated for each patient
group, and the top 25 upregulated probe sets were plotted.
RT-PCR. RNA was extracted from cells using TRI zol (Invitrogen).
cDNA transcription was performed using the first strand synthesis kit
(Invitrogen) per the manufacturer’s instructions. RNA (1 μg) was used
in each 20-μl reaction system. For semiquantitative PCR or real-time
PCR, 1 μl cDNA production from each reaction and 150 pM 5′ primer
and 150 pM 3′ primer was used in a 25-μl reaction system. Primers were
as follows: ODC forward, 5′-TTGCCACTGATGATTCCAAA-3′; ODC
reverse, 5′-GAACTTCAGGGTCAGCTTGC-3′; GFP forward, 5’GGACGTGGTTT TCCTTTGAA-3′; GFP reverse, 5′-AGCCACCACCAATATCAAGC-3′; Mcl1 forward, 5′-GGTGCCTTTGTGGCCAAACACTTA-3′;
Mcl1 reverse, 5′-ACCCATCCCAGCCTCTTTGTTTGA-3′; Actin forward,
5′-GCTGTATTCCCCTCCATCGTG-3′; Actin reverse, 5′-CACGGTTGGCCTTAGGG TTCAG-3′. In semiquantitative PCR, reaction was terminated every 2 cycles beginning at the 16th cycle, which was determined
by preliminary experiments. GFP was used as loading control. Real-time
PCR was carried out using a SYBR Green real-time PCR system (Applied
Biosystem). β-Actin was used as cDNA quantity calibration. Primers for
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Mcl1fl PCR were 5′-CTGAGAGTTGTACCGGACAA-3′ and 5′-GCAGTACAGGTTCAAGCCGATG-3′.
Ligation-mediated PCR and integration site analysis. Retroviral integration
sites were analyzed in DNA samples isolated from splenocytes derived from
either MSCV-Myc leukemic mice or MSCV-GFP control mice using ligationmediated PCR (Supplemental Methods).
Statistics. Statistical comparisons were made using Student’s 2-sided
t test. P values of 0.05 or less were considered significant.
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